Hudson Bay Capital Management LP Insmed Inc Transaction History

Hudson Bay Capital Management LP

$24.1 Billion
Q4 2024

A detailed history of Hudson Bay Capital Management LP transactions in Insmed Inc stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 85,000 shares of INSM stock, worth $6.59 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

85,000

Previous 240,000 64.58%

Holding current value

$6.59 Million

Previous $17.5 Million 66.51%

% of portfolio

0.02%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $1.99 Million - $2.3 Million	-30,000 Reduced 12.5%	210,000 $14.5 Million
Q3 2024 Nov 13, 2024	SELL	$62.0 - $79.01 $14.1 Million - $18 Million	-227,500 Reduced 48.66%	240,000 $17.5 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $3.5 Million - $11.1 Million	-159,310 Reduced 25.42%	467,500 $31.3 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $4.1 Million - $4.77 Million	159,310 Added 34.08%	626,810 $17 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $8.9 Million - $12.1 Million	-380,000 Reduced 44.84%	467,500 $14.5 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $16.9 Million - $23 Million	-852,500 Reduced 50.15%	847,500 $21.4 Million
Q2 2023 Aug 14, 2023	SELL	$16.44 - $21.1 $616,500 - $791,250	-37,500 Reduced 2.16%	1,700,000 $35.9 Million
Q1 2023 May 16, 2023	BUY	$16.26 - $21.73 $10.9 Million - $14.5 Million	668,368 Added 62.52%	1,737,500 $29.6 Million
Q1 2023 May 15, 2023	SELL	$16.26 - $21.73 $5.34 Million - $7.14 Million	-328,368 Reduced 23.5%	1,069,132 $18.2 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $11.4 Million - $15.6 Million	672,500 Added 92.76%	1,397,500 $27.9 Million
Q3 2022 Nov 14, 2022	SELL	$20.88 - $28.21 $1.24 Million - $1.67 Million	-59,300 Reduced 7.56%	725,000 $15.6 Million
Q2 2022 Aug 12, 2022	BUY	$17.07 - $25.71 $10.7 Million - $16.1 Million	624,300 Added 390.19%	784,300 $15.5 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $2.65 Million - $3.66 Million	130,000 Added 433.33%	160,000 $3.76 Million
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $776,700 - $1 Million	30,000 New	30,000 $817,000
Q1 2021 May 14, 2021	SELL	$32.28 - $44.3 $645,600 - $886,000	-20,000 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$31.45 - $40.54 $2.52 Million - $3.24 Million	-80,000 Reduced 80.0%	20,000 $666,000
Q3 2020 Nov 12, 2020	SELL	$26.0 - $34.5 $260,000 - $345,000	-10,000 Reduced 9.09%	100,000 $3.21 Million
Q2 2020 Aug 12, 2020	SELL	$14.11 - $29.42 $1.69 Million - $3.53 Million	-120,000 Reduced 52.17%	110,000 $3.03 Million
Q1 2020 May 14, 2020	BUY	$13.63 - $33.98 $1.77 Million - $4.42 Million	130,000 Added 130.0%	230,000 $3.69 Million
Q4 2019 Feb 12, 2020	SELL	$16.12 - $24.98 $483,600 - $749,400	-30,000 Reduced 23.08%	100,000 $2.39 Million
Q3 2019 Nov 13, 2019	BUY	$15.49 - $25.78 $2.01 Million - $3.35 Million	130,000 New	130,000 $2.29 Million
Q1 2019 May 15, 2019	SELL	$13.91 - $31.15 $2.09 Million - $4.67 Million	-150,000 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$11.6 - $18.7 $580,000 - $935,000	50,000 Added 50.0%	150,000 $1.97 Million
Q3 2018 Nov 14, 2018	SELL	$18.95 - $28.08 $758,000 - $1.12 Million	-40,000 Reduced 28.57%	100,000 $2.02 Million
Q2 2018 Aug 13, 2018	SELL	$20.0 - $29.72 $1 Million - $1.49 Million	-50,000 Reduced 26.32%	140,000 $3.31 Million
Q1 2018 May 14, 2018	BUY	$21.69 - $32.99 $1.52 Million - $2.31 Million	70,000 Added 58.33%	190,000 $4.28 Million
Q4 2017 Feb 12, 2018	SELL	$26.43 - $31.78 $528,600 - $635,600	-20,000 Reduced 14.29%	120,000 $3.74 Million
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $1.63 Million - $4.37 Million	140,000	140,000 $4.37 Million

Others Institutions Holding INSM

# of Institutions

497

Shares Held

189M

Call Options Held

3.21M

Put Options Held

2.72M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.5B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Insmed Inc Transaction History